Synmosa Biopharma announced that its board approved the company’s financial results for the first three quarters of 2025. Cumulative net income after tax reached NT$632 million, up 16% year-on-year, with earnings per share (EPS) of NT$1.28. Based on first-half figures, third-quarter net profit after tax is estimated at NT$207 million, a 27% increase from the same period last year, with a quarterly EPS of approximately NT$0.41.

The company also reported that consolidated revenue for October reached NT$540 million, marking the highest October on record with a 9% year-on-year increase. Cumulative revenue for the first ten months totaled NT$5.14 billion, up 13% from the same period last year.

Synmosa noted that across its product divisions, sales of cardiovascular and oncology products maintained high double-digit growth. The group also continued to launch multiple high-quality products in the OTC and health supplement markets.

Resource: 健喬2025年前三季 EPS 1.28元